Understanding how nuclear proteins affect immune responses in cancer
Determining the role of nuclear envelope reformation proteins in regulating the cGAS/STING innate immune response in cancer
This study is looking at how certain proteins that help rebuild the cell's protective layer can affect the immune system's response to cancer, with the goal of finding better ways to improve cancer treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10912518 on NIH RePORTER |
What this research studies
This research investigates how certain proteins involved in the reformation of the nuclear envelope influence the immune response to cancer cells. It focuses on the cGAS/STING pathway, which detects DNA from damaged cancer cells and can either help or hinder cancer treatment. By using specific DNA models, the research aims to uncover the interactions between these nuclear proteins and the immune response, potentially leading to new therapeutic strategies. Patients may benefit from insights that could improve immunotherapy effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancer who may benefit from enhanced immunotherapy approaches.
Not a fit: Patients with non-cancerous conditions or those not undergoing immunotherapy may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the effectiveness of immunotherapies.
How similar studies have performed: Other research has shown promising results in understanding immune responses in cancer, but the specific role of nuclear envelope reformation proteins in this context is still being explored.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Isenhour, Anthony Wayne — Yale University
- Study coordinator: Isenhour, Anthony Wayne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.